Dr A Mark Richards
Director, Cardiovascular Research Institute, NUHS, Singapore
 

How NT-proBNP Made a Difference: Dr Richards’ Patient Story

KEY TAKEAWAYS

  • NT-proBNP helps to rapidly rule-In Heart Failure and the initiation of appropriate management to reduce future complications of this condition

Transcript of the above video:

I remember receiving a telephone call about a young farmer who had been seeing his doctor for a couple of months, with increasing shortness of breath on exertion – and he’d been diagnosed as asthma. Asthma ran in the family – had a sister with asthma.There was a little bit of wheezing at times, but he would, clearly wasn’t getting any better. He had done some tests and NT-proBNP was ticked. I think as a kind of second thought.

It came back clearly at an elevated level for a man of 48 years, which he was. And having heard that level, I knew that in young people, especially those under 50 years or so, an elevated NT-proBNP is a very, very high marker, gives very high likelihood of heart failure being present. It’s actually at that age, not only a good rule-out test, but a very good rule-in test. I was quite confident he had heart failure, and had him sent in and indeed, he was developing a cardiomyopathy which had not been recognised. And clearly it was caught and treated and the subsequently done very well. And I think that test probably saved him from deteriorating into frank severe decompensation with pulmonary edema coming in desperately ill on one occasion.

President of APSC Cofound of digital trends in Asia

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy.

28 March 2023
Prof Alexandre Mebazaa

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi